Current Headlines

1. FDA Update: March 22, 2010
   3/19/2010
2. Agendia To Play Pivotal Role In ISPY-2 Trial For Breast Cancer
   3/19/2010
   Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites.
3. Anti-Obesity Drugs Unlikely To Provide Lasting Benefit According To Scientists
   3/19/2010
   Scientists at the University of Liverpool argue that anti-obesity drugs fail to provide lasting benefits for health and wellbeing because they tackle the biological consequences of obesity, and not the important psychological causes of overconsumption and weight gain.
4. Brand Protection And Cost Savings With Dynamic Weighing And Contaminant Detection In One Compact System
   3/19/2010
   Mettler-Toledo Hi-Speed, the worldwide leader of in-line checkweighing, announces the launch of the new XS3 AdvanChek X-ray CombiWeigher, which combines world-leading checkweighing and x-ray inspection technologies in one revolutionary and unique, space-saving system.
5. Teva To Acquire Ratiopharm
   3/18/2010
   Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany's second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of 3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals.
6. Alpharma To Pay $42.5M To Resolve False Claims Act Allegations In Connection With Promotion Of Drug Kadian
   3/18/2010
   American pharmaceutical manufacturer Alpharma Inc. has agreed to pay $42.5M to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug, Kadian, the Justice Department announced today.
7. WHO Extends Prequalification Of Merck's ROTATEQ For Global Use
   3/18/2010
   ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent), the vaccine from Merck that helps prevent rotavirus gastroenteritis in infants and children, has received an extension of its prequalification status by the World Health Organization (WHO), to include its use in Asia and Africa.
8. Astellas Responds To OSI Pharmaceuticals’ Rejection
   3/18/2010
   Astellas Pharma Inc. recently released the following statement in response to OSI Pharmaceuticals' rejection of Astellas' tender offer for $52.00 per share.
9. UltraCap® H.D. Capsule In 40-Inch Length Provides Large Volume Filtration
   3/18/2010
   UltraCap® H.D. (Heavy Duty) single-use high capacity capsule filters provide high flow rates and high throughput, in lengths up to 40 inches (100 cm) for large volume filtration.
10. Abbott Enhances Pharmaceutical Pipeline With Acquisition Of Facet Biotech
    3/18/2010
    Abbott (NYSE: ABT) and Facet Biotech Corporation (Nasdaq: FACT) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.

First 1 2 3 4 5 6 7 8 9 10 10 (Last)